FAQ: Calidi Biotherapeutics' $6 Million Public Offering and Company Overview

What is the main announcement in this content?

Calidi Biotherapeutics has priced an underwritten public offering for gross proceeds of $6 million before expenses, consisting of common stock units and pre-funded warrant units paired with Series I warrants.

What specific securities are being offered in this public offering?

The offering includes approximately 1.47 million common stock units priced at $2.00 each and about 1.53 million pre-funded warrant units priced at $1.999 each, both paired with Series I warrants exercisable at $2.00 per share for five years.

Who is managing this public offering?

Ladenburg Thalmann is serving as sole book-running manager with Laidlaw & Company (U.K.) Ltd. as co-manager for the offering.

What type of company is Calidi Biotherapeutics?

Calidi Biotherapeutics is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease.

What is Calidi’s proprietary technology platform?

The company’s proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, shielding the virus from immune clearance to effectively reach tumor sites.

What cancers is Calidi’s lead candidate targeting?

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need.

Where can investors find more information about Calidi Biotherapeutics?

The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI, and the full press release can be viewed at https://ibn.fm/LN7Xe.

What is TinyGems and its role in this content?

TinyGems is a specialized communications platform focused on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio at IBN that provides various corporate communications solutions including press distribution and social media outreach.